All In Biotech

Drug Trial Radar · NCT02099123

A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)

A Study of STAtins for Reducing Events in the Elderly (STAREE)

Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 9,971 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

9,971

Actual

Start

Jul 2015

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Monash UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Health and Medical Research Council, Australia; National Heart Foundation, Australia
First posted
Mar 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The STAREE study will examine whether treatment with statin (atorvastatin 40mg) compared with placebo will prolong disability free survival and reduce major cardiovascular events amongst healthy elderly people (≥70 years).

Conditions

  • Independent Living
  • Disability Free Survival
  • Elderly
  • Healthy

Interventions

  • AtorvastatinDrug

    Atorvastatin 20 mg tablet

  • Placebo (for Atorvastatin)Drug

    Inactive pill manufactured to mimic Atorvastatin 20 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disability free survival - death or development of dementia or development of persistent physical disabilityTime frame: Time from randomisation to a primary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years.
  2. Major cardiovascular eventsTime frame: Time from randomisation to a primary endpoint or censoring at the end of study follow-up which is anticipated to be an average 6 years.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Queensland

    Brisbane, Australia

  • New South Wales

    Newcastle, Australia

  • Western Australia

    Perth, Australia

  • Tasmania

    Hobart, Tasmania, Australia

  • Victoria

    Melbourne, Victoria, Australia

  • South Australia

    Adelaide, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.